ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2144

Early RA Patients Fulfilling the New 2010 ACR/EULAR Criteria, Display Better Clinical Responses to DMARD Therapy but Have Higher Radiographic Damage Progression Than Patients with Early RA Not Fulfilling the 2010 ACR/EULAR Criteria

Ruediger Mueller1, Toni Kaegi1, Axel Finckh2 and Johannes von Kempis1, 1Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 2Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Diagnostic criteria, radiography, rheumatic disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: New ACR/EULAR criteria for the classification of rheumatoid arthritis (RA) were recently proposed. The aim of this analysis was to examine the impact of fulfilling the 2010 ACR/EULAR criteria at the initial visit on long-term progression of disease and radiographic progression.

Methods: For this observational cohort study within the Swiss RA registry SCQM, we included patients suffering from early RA or undifferentiated arthritis (UA, disease duration ≤1 year), as defined by the treating rheumatologist, who had not received any previous DMARDs. Baseline diagnosis of RA/UA was reassessed according to the 2010 ACR/EULAR criteria at baseline. Patients were separated into 2 groups depending on whether or not they fulfilled the 2010 ACR/EULAR criteria at baseline (≥ 6 points versus < 6 points). The primary outcome measures were the DAS 28 and erosions as measured by the Ratingen score over time.

Results: A total number 592 patients was analysed. 352 of them fulfilled the 2010 ACR/EULAR at baseline, 240 were not classifiable as RA according to the new criteria at baseline. The score calculated by the new ACR/EULAR criteria correlated with disease activity at disease onset. Treatment was initiated with DMARDs, mostly MTX, in all patients. There were no significant differences in the therapeutic strategies between patients fulfilling the classification criteria or not. The patients fulfilling ACR/EULAR criteria at baseline developed a 39.1%reduction of DAS 28 scores, as compared to a 33.6%reduction in ACR/EULAR-negative patients after 6 months, independent of their respective treatments. After 1 year of follow-up no differences were found comparing the mean DAS28 scores in the 2 groups. Average radiographic progression was higher among ACR/EULAR-positive patients (progression of Ratingen score/year 0.50 vs. 0.32, resp., p=0.03) after 3 years of follow up.

Conclusion: The 2010 ACR/EULAR criteria appeared to select a subset of patients among early RA/UA patients with a favourable clinical response to conventional anti-rheumatic therapy. Despite this therapy, radiographic progression was higher in 2010 ACR/EULAR positive patients.


Disclosure:

R. Mueller,
None;

T. Kaegi,
None;

A. Finckh,

Roche, Pfizer, BMS,

2,

Roche, Pfizer, BMS,

5;

J. von Kempis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-ra-patients-fulfilling-the-new-2010-acreular-criteria-display-better-clinical-responses-to-dmard-therapy-but-have-higher-radiographic-damage-progression-than-patients-with-early-ra-not-fulfill/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology